SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
MRVI

Maravai Lifesciences Holdings, Inc. (NASDAQ:MRVI)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$6.98-$0.21 (-2.92%)
 
Market cap
$1.98B
Insider Score
Health Score
Analyst consensus
Listed since
Nov 20, 2020
Market Cap$1.98B+89.7%
Revenue (ttm)$213.00M+10.8%
Net Income-$65.67M+45.8%
EPS-$0.45+47.0%
Shares Out149.25M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,785,366
Open$7.08
Previous Close$7.19
Day's Range$6.91 - $7.16
52-Week Range$2.80 - $9.42
Beta0.63
AnalystsBuy
Price Target$9.50(+36.10%)
Earnings DateFeb 24, 2027

About MRVI

Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.

Address
10770 Wateridge Circle, San Diego, CA, 92121, US
Market Cap
1.98 billion
Employees
410
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceBalanced
Sold
$254.00K
Bought
$178.10K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy1 Hold0 SellAvg target $7.83 (+12.2%)

2 firms rating MRVI in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From MRVI’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-2.92%
5 Days
-4.38%
1 Month
-1.27%
6 Months
+58.64%
1 Year
+89.67%

$MRVI stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in MRVI holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by MRVI's directors and management

Net Shares Purchased by Insiders−50k−25k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

MRVI Estimated quarterly lobbying spending

Source: U.S. Senate LDA

MRVI Revenue by Segment or Geography

$45.85MTotal
TriLink$28.35M61.83%
Cygnus$17.50M38.17%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New MRVI patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to MRVI from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in MRVI

VTIVanguard Morningstar Total Stock Market ETF$22.81M
IWMiShares Russell 2000 ETF$21.27M
VXFVanguard Extended Market ETF$11.20M
IWNiShares Russell 2000 Value ETF$7.48M
FYCFirst Trust Small Cap Growth AlphaDEX Fund$6.45M
IBBiShares Biotechnology ETF$6.00M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from MRVI’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
9.96
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
72

News check: KeyBanc upgrade to Overweight with $11 price target signals analyst confidence in MRVI's prospects.

Recent Insider Activity

Buys
1
Sells
2
Buy Value
$178.10K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

FESCFirst Eagle Small Cap Equity ETF0.98%
NIXTResearch Affiliates Deletions ETF0.89%
GNOMGlobal X - Genomics & Biotechnology ETF0.62%
FYCFirst Trust Small Cap Growth AlphaDEX Fund0.51%
AESBHarbor AlphaEdge Small Cap Core ETF0.28%
FYXFirst Trust Small Cap Core AlphaDEX Fund0.24%
FSCCFederated Hermes MDT Small Cap Core ETF0.17%
FSEVFidelity Enhanced Small Cap Value ETF0.16%
KOMPState Street SPDR S&P Kensho New Economies Composite ETF0.14%
FADFirst Trust Multi Cap Growth AlphaDEX Fund0.10%
GINNGoldman Sachs Innovate Equity ETF0.10%
VFMOVanguard U.S. Momentum Factor ETF0.10%

Weight is the stock’s share of each fund’s holdings.